After a few years of high hopes and disappointing starts, the histone deacetylase field appears to be maturing. Deal activity has picked up, and a few promising agents targeting advanced cancers are nearing late stage trials.
Massachusetts-based Syndax has taken a different tack from its HDAC competitors; it aims to resensitize the tumors of patients who are resistant to commonly used cancer drugs. “The Pink Sheet” caught up with Syndax Pharmaceuticals Inc. CEO Joanna Horobin at the BIO CEO conference Feb. 13 in New York
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?